CymaBay Therapeutics, Inc. (CBAY) |
|
14.68 -0.23 (-1.54%)
|
10-02 16:00 |
|
Open: |
14.82 |
Pre. Close: |
14.91 |
|
High:
|
15.175 |
Low:
|
14.53 |
|
Volume:
|
1,346,211 |
Market Cap:
|
1,654(M) |
|
|
|
Technical analysis |
as of: 2023-10-02 4:48:58 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 19.02  One year: 21.25 |
| Support: |
Support1: 13.19 Support2: 10.98 |
| Resistance: |
Resistance1: 16.29 Resistance2: 18.2 |
| Pivot: |
15.5  |
| Moving Average: |
MA(5): 15.01 MA(20): 15.42
MA(100): 11.73 MA(250): 8.63 |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.5 |
| Stochastic oscillator: |
%K(14,3): 23.4 %D(3): 29.9 |
| RSI: |
RSI(14): 49.6 |
| 52-week: |
High: 18.2 Low: 3.15 |
| Average Vol(K): |
3-Month: 2,120 (K) 10-Days: 2,141 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CBAY ] has closed above bottom band by 29.2%. Bollinger Bands are 29.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
15.19 - 15.27 |
15.27 - 15.34 |
|
Low:
|
14.33 - 14.43 |
14.43 - 14.52 |
|
Close:
|
14.53 - 14.68 |
14.68 - 14.81 |
|
Company Description |
|
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. |
Headline News |
Sat, 30 Sep 2023
Kurt Von Emster Sells 15921 Shares of CymaBay Therapeutics, Inc ... - MarketBeat
Tue, 26 Sep 2023
UBS Maintains Cymabay Therapeutics (CBAY) Buy Recommendation - Nasdaq
Tue, 26 Sep 2023
Should You Hold CymaBay Therapeutics Inc (CBAY) in Biotechnology Industry? - InvestorsObserver
Sun, 24 Sep 2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Given Consensus ... - MarketBeat
Thu, 21 Sep 2023
CymaBay Therapeutics Launches Confirmatory Study for Seladelpar ... - Best Stocks
Mon, 11 Sep 2023
Why CymaBay Therapeutics Stock Popped Again Today - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
113 (M) |
| Shares Float |
89 (M) |
|
% Held by Insiders
|
0.3 (%) |
|
% Held by Institutions
|
92.8 (%) |
|
Shares Short
|
8,960 (K) |
|
Shares Short P.Month
|
11,430 (K) |
Stock Financials |
|
EPS
|
-0.84 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.11 |
|
Profit Margin (%)
|
-260.3 |
|
Operating Margin (%)
|
-231.6 |
|
Return on Assets (ttm)
|
-22.3 |
|
Return on Equity (ttm)
|
-84.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.37 |
|
Sales Per Share
|
0.27 |
|
EBITDA (p.s.)
|
-0.64 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-55 (M) |
|
Levered Free Cash Flow
|
-45 (M) |
Stock Valuations |
|
PE Ratio
|
-17.48 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
13.22 |
|
Price to Sales
|
53.32 |
|
Price to Cash Flow
|
-29.93 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
